Table 3 Cardiac magnetic resonance imaging results at baseline and follow-up
Variable | Anti-HER2 treatment (n = 24) | Trastuzumab and pertuzumab treatment (n = 16) | Trastuzumab treatment (n = 8) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Baseline | Follow-up | p-value | Baseline | Follow-up | p-value | Baseline | Follow-up | p-value |
LV ejection fraction (%) | 63.00 (61.3, 66.8) | 59.0 (55.0, 60.0) |  < 0.001 | 63.0 (61.0, 65.8) | 57.5 (55.0, 60.0) |  < 0.001 | 65.3 ± 4.0 | 58.5 ± 3.8 | 0.002 |
LV end-diastolic volume index (mL/m2) | 64.7 ± 17.3 | 65.1 ± 13.3 | 0.880 | 68.6 (53.5, 73.9) | 62.4 (53.5, 74.2) | 0.836 | 68.8 ± 13.5 | 65.9 ± 10.6 | 0.253 |
LV end-systolic volume index (mL/m2) | 22.1 (18.8, 28.6) | 25.6 (21.6, 31.9) | 0.001 | 23.8 (18.9, 28.6) | 26.76 (21.2, 31.9) | 0.015 | 23.7 ± 6.0 | 27.6 ± 6.5 | 0.005 |
LV mass index (g/m2) | 39.4 ± 9.3 | 38.9 ± 8.5 | 0.536 | 40.2 ± 10.5 | 39.5 ± 9.4 | 0.544 | 37.8 ± 6.6 | 37.5 ± 6.5 | 0.854 |
Stroke volume index (mL/m2) | 42.3 ± 7.0 | 36.8 ± 5.8 |  < 0.001 | 40.9 ± 6.4 | 36.01 ± 6.2 | 0.006 | 45.1 ± 7.7 | 38.2 ± 4.8 | 0.007 |
Cardiac index (L/m2) | 3.2 ± 0.6 | 2.9 ± 0.5 | 0.003 | 3.0 ± 0.6 | 2.8 ± 0.5 | 0.026 | 3.5 ± 0.6 | 3.1 ± 0.4 | 0.075 |
Global radial strain | 33.2 ± 7.1 | 29.3 ± 6.0 |  < 0.001 | 33.1 ± 8.0 | 28.3 ± 6.1 | 0.002 | 33.5 ± 5.2 | 31.4 ± 5.6 | 0.045 |
Global circumferential strain | -18.8 ± 2.4 | -17.4 ± 2.4 |  < 0.001 | -18.7 ± 2.7 | -17.0 ± 2.5 | 0.001 | -19.1 ± 1.8 | -18.3 ± 2.1 | 0.078 |
Global longitudinal strain | -16.0 ± 1.6 | -15.0 ± 2.0 | 0.004 | -15.7 ± 1.8 | -14.5 ± 2.0 | 0.014 | -16.5 ± 0.9 | -15.9 ± 1.8 | 0.169 |
T1 relaxation time (ms) | 1,228.4 ± 37.8 | 1,246.4 ± 44.7 | 0.031 | 1,224.9 ± 44.1 | 1,241.7 ± 48.2 | 0.120 | 1,235.5 ± 20.6 | 1,255.7 ± 38.0 | 0.150 |
T2 relaxation time (ms) | 48.1 ± 2.5 | 49.4 ± 2.8 | 0.025 | 48.23 ± 2.25 | 49.04 ± 2.77 | 0.191 | 47.96 ± 2.97 | 50.2 ± 2.7 | 0.074 |